Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: A retrospective multicenter study (KROG 21-06)
- Authors
- Park, Younghee; Shin, Young Seob; Kim, Kyubo; Shin, Kyung Hwan; Chang, Ji Hyun; Kim, Su Ssan; Jung, Jin Hong; Park, Won; Kim, Haeyoung; Kim, Yong Bae; Ahn, Sung Ja; Kim, Myungsoo; Kim, Jin Hee; Cha, Hye Jung; Kim, Tae Gyu; Park, Hae Jin; Lee, Sun Young
- Issue Date
- Mar-2023
- Publisher
- ELSEVIER SCI LTD
- Keywords
- Breast cancer; Neoadjuvant chemotherapy; Residual nodal disease; Sentinel lymph node biopsy; Axillary lymph node dissection
- Citation
- EJSO, v.49, no.3, pp.589 - 596
- Indexed
- SCIE
SCOPUS
- Journal Title
- EJSO
- Volume
- 49
- Number
- 3
- Start Page
- 589
- End Page
- 596
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/185109
- DOI
- 10.1016/j.ejso.2022.11.099
- ISSN
- 0748-7983
- Abstract
- Background
We evaluated the impact of omitting axillary lymph node dissection (ALND) on oncological outcomes in breast cancer patients with residual nodal disease after neoadjuvant chemotherapy (NAC).
Methods
The medical records of patients who underwent NAC followed by surgical resection and had residual nodal disease were retrospectively reviewed. In total, 1273 patients from 12 institutions were included; all underwent postoperative radiotherapy. Axillary surgery consisted of ALND in 1103 patients (86.6%) and sentinel lymph node biopsy (SLNBx) alone in 170 (13.4%). Univariate and multivariate analyses of disease-free survival (DFS) and overall survival (OS) were performed before and after propensity score matching (PSM).
Results
The median follow-up was 75.3 months (range, 2.5–182.7). Axillary recurrence rates were 4.8% in the ALND group (n = 53) and 4.7% in the SLNBx group (n = 8). Before PSM, univariate analysis indicated that the 5-year OS rate was inferior in the ALND group compared to the SLNBx group (86.6% vs. 93.3%, respectively; P = 0.002); multivariate analysis did not show a difference between groups (P = 0.325). After PSM, 258 and 136 patients were included in the ALND and SLNBx groups, respectively. There were no significant differences between the ALND and SLNBx groups in DFS (5-year rate, 75.8% vs. 76.9%, respectively; P = 0.406) or OS (5-year rate, 88.7% vs. 93.1%, respectively; P = 0.083).
Conclusions
SLNBx alone did not compromise oncological outcomes in patients with residual nodal disease after NAC. The omission of ALND might be a possible option for axillary management in patients treated with NAC and postoperative radiotherapy.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 방사선종양학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/185109)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.